SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE), creators of the patented antimicrobial, silver dihydrogen citrate (SDC), today reported revenues for the fiscal year ended July 31, 2008 of $1,487,500, which increased more than 340% compared with $336,400 in the prior fiscal year. The Company reported a loss from operations before taxes of $(6,540,300), or $(0.24) per share, compared with a loss of $(4,654,900), or $(0.19) per share, in the prior year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

Included in the loss from operations before taxes for the fiscal year ended July 31, 2008 was $2,638,000 of non-cash expense, including stock-based compensation, amortization and depreciation, compared with $1,796,900 of such non-cash expense for the year ended July 31, 2007.

During the fourth quarter of its fiscal year, PURE announced new distribution agreements with Orchem Corporation and DuraBan International, two recognized organizations with established sales channels which will shortly begin to market SDC-based products. In addition, the Company announced that its distribution partner in Brazil had received approval to manufacture and sell SDC-based disinfectant. Finally, PURE entered into an agreement with FTA Therapeutics, LLC for the development and licensing of additional silver dihydrogen citrate (SDC)-based products for human use. FTA has already begun initial formulation and clinical projects for FDA-regulated dermatology, wound care and medical biofilm control products containing SDC.

Earlier in the year, the company signed an agreement with Rockline Industries, Inc., for North American distribution of PURE's ready-to-use disinfectant product and for the development and North American distribution of wipes products as well as new disinfectant, sanitizer and preservative products containing SDC. Rockline is the market leader in the manufacture and distribution of wipes. In addition, PURE received approval for expanded efficacy claims by the EPA and broadened its patent portfolio; and our common stock commenced trading on the Nasdaq exchange and was added as a component of the Russell Microcap Index.

"During fiscal 2008, we strengthened our competitive position and built upon our private label distribution network culminating in an outstanding fourth quarter in which we posted more than $820,000 in revenue," said Michael L. Krall, President and CEO of PURE Bioscience. "PURE established and continues to make important strides toward finalizing additional contracts with major market players for the integration of SDC into third party products, including a new partnership with a respected leader for the development of FDA-regulated SDC products.

"It is important to note that virtually all of our initiatives within major markets and with world-class partners remain under continuing discussion and negotiation. Furthermore, we have identified a number of large new markets for SDC for agriculture and water applications, particularly within growing developing countries around the world. Finally, regulatory and legislative changes, as well as consumer and competitive pressures are driving companies to explore, review and adopt 'green' and environmentally favorable solutions like SDC, the first new anti-microbial approved by the EPA in over thirty years.

"The size of potential markets and the breadth of applications for our technology continue to grow," concluded Mr. Krall. "From our presentations and meetings across various sectors and country borders, with current, pending and potential industry-leading partners, I have never been more encouraged and confident in the soundness of our strategy, the focus of our execution and the enormous opportunities for growth and success for PURE Bioscience."

The Company has scheduled a conference call to present year end-results on Thursday, October 16, 2008 at 4:30 PM ET. The conference call will consist of prepared remarks from management and will be available over the Internet via live web cast at http://www.purebio.com. Shareholders can submit questions for the conference call via e mail through the investor section of the company web page at http://www.purebio.com.

The conference call will also be accessible by telephone at (800) 309-1352 (no passcode required) and participants are advised to dial-in at least five minutes before the scheduled start time. The replay of the conference call will be available for seven days by telephone at (888) 203-1112 or (719) 457-0820 using passcode 3067874. The webcast will be archived for a period of 90 days at http://www.purebio.com

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

     PURE Bioscience Investor Contact:
     Paul G. Henning, Vice President
     Cameron Associates
     (212) 554-5462
     paul@cameronassoc.com



                               PURE Bioscience

                         CONSOLIDATED BALANCE SHEETS

                                                           July 31,
                                                   2008               2007
    ASSETS
    Current Assets
      Cash and cash equivalents                 $2,024,400           $735,654
      Short-term investments                     4,607,888            708,058
      Accounts receivable, net of allowance
       for doubtful accounts of $0 at
       July 31, 2007 and $0 at July 31, 2008       834,721              7,548
      Inventories, net                             370,043            242,899
      Prepaid expenses                              52,560                  -
        Total current assets                     7,889,612          1,694,159

    Total property, plant and equipment, net     1,034,835            968,737

    Other Assets
      Prepaid consulting                                 -             13,011
      Deposits                                           -              9,744
      Patents                                    2,016,391          2,176,388

      Total assets                             $10,940,838         $4,862,039

    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current Liabilities
      Accounts payable                            $596,132           $422,753
      Accrued liabilities                          126,141             77,228
      Deferred revenue                             256,793                  -
      Taxes payable                                  2,400              2,400
        Total current liabilities                  981,466            502,381

    Deferred rent                                   15,798                  -

        Total liabilities                          997,264            502,381

    Stockholders' Equity
      Preferred Stock, no par value:
        5,000,000 shares authorized,
         no shares issued                                -                  -
      Class A common stock, no par value:
        50,000,000 shares authorized
        24,961,805 issued and outstanding at
         July 31, 2007, and 29,573,936 issued
         and outstanding at July 31, 2008       35,436,077         26,519,543
      Additional Paid-In Capital                 4,155,608          2,486,829
      Warrants:
        391,698 issued and outstanding at
         July 31, 2007, and 880,351 issued
         and outstanding at July 31, 2008        1,766,159            245,825
      Accumulated other comprehensive income        18,588                  -
      Accumulated deficit                      (31,432,858)       (24,892,539)
        Total stockholders' equity               9,943,574          4,359,658

    Total liabilities and stockholders'
     equity                                    $10,940,838         $4,862,039



                               PURE Bioscience

                    CONSOLIDATED STATEMENTS OF OPERATIONS


                                                     For the Years Ended
                                                           July 31,
                                                   2008              2007

    Net revenues                                $1,487,464          $336,392
    Cost of sales                                  463,596           221,108

    Gross profit                                 1,023,868           115,284

    Selling expenses                               805,628           899,145
    General and administrative expenses          5,142,961         2,836,224
    Research and development                     1,646,352         1,220,764
    Impairment of capitalized assets               109,286               -

    Total operating expenses                     7,704,227         4,956,133

    Loss from operations                        (6,680,359)       (4,840,849)

    Other income and (expense):
      Interest income                               30,786           150,878
      Interest expense                                 -                 -
      Other                                        111,654            37,494

    Total other income (expense)                   142,440           188,372

    Net loss before income taxes                (6,537,919)       (4,652,477)
    Income tax provision                            (2,400)           (2,400)

    Loss from continuing operations             (6,540,319)       (4,654,877)

    Discontinued operations:
      Income taxes on discontinued operations            -                 -

    Net loss                                    (6,540,319)       (4,654,877)

    Net loss per common share, basic and diluted
      Continuing operations                         $(0.24)           $(0.19)
      Discontinued operations                            -                 -
      Net Loss                                      $(0.24)           $(0.19)

    Weighted average common shares used in
     computing basic and diluted net loss
     per common share                           27,553,215        24,432,905

SOURCE PURE Bioscience